JAK1 and rheumatoid arthritis: Peripheral blood neutrophils from patients with RA migrate along an IL-8 chemotactic gradient in a JAK2-dependent manner; in vitro, this process was sensitive to the JAK1–JAK2 inhibitor baricitinib but not the JAK3–JAK1 inhibitor tofacitinib [45].